Future Of Merit Medical Systems: Analyst Predictions On Revenue Growth And Operating Margin Improvement
Portfolio Pulse from Nabaparna Bhattacharya
Needham analyst Mike Matson reiterated a Buy rating on Merit Medical Systems (MMSI) and raised the price target to $96 from $90 after the company acquired Dialysis and Biopsy products from AngioDynamics (ANGO) for $100 million. Matson expects revenue growth to return to mid-single digits or better and EPS growth to return to 15%+ for MMSI.
June 09, 2023 | 6:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merit Medical Systems acquired Dialysis and Biopsy products from AngioDynamics for $100 million, leading to a raised price target of $96 by Needham analyst. Revenue and EPS growth expected.
The acquisition of Dialysis and Biopsy products from AngioDynamics is expected to boost MMSI's revenue growth and EPS, leading to a raised price target by Needham analyst. This positive outlook is likely to have a short-term positive impact on MMSI's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
AngioDynamics sold its Dialysis and Biopsy products to Merit Medical Systems for $100 million.
While the sale of Dialysis and Biopsy products to MMSI generates $100 million for AngioDynamics, the impact on ANGO's stock price is uncertain in the short term as the deal may be seen as a strategic move to focus on other areas of their business.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50